GSK R&D President Patrick Vallance On Increasing R&D Productivity: An Interview With PharmAsia News (Part 1 of 2)
This article was originally published in PharmAsia News
Executive Summary
An R&D model aimed at bringing the pressure and promise of startups to life within GlaxoSmithKline PLC continues to be tweaked, according to Patrick Vallance, president of pharmaceuticals R&D. He sat down with PharmAsia News during a recent visit to Singapore to give an overview of the company’s strategy.
You may also be interested in...
Glaxo Confident In Output From Its Revamped R&D Engine
Britain’s biggest drug maker updated the investment community on its pipeline prospects Dec. 3, outlining a timescale of three pipeline “waves” that will include pivotal clinical trial results on up to 14 medicines in the next two years.
GSK Offers a Window Into Attempts at Biotech-like R&D
During a nearly two-hour R&D seminar, executives at GlaxoSmithKline PLC described the company's evolving strategy, detailing the organization's goals, capital allocation, and productivity performance, and providing a glimpse into the ongoing work within six of its 40 biotech-like discovery performance units.
List Ahead For Southeast Asia Pharma In 2015
PharmAsia News looks ahead at 2015 to highlight expected trends and events shaping the biomedical community in Southeast Asia.